Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer The TRANSFORMER (Testosterone Revival Abolishes Negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results